Immune Checkpoint Inhibitor-induced Pneumonitis: Incidence, Clinical Characteristics, and Outcomes

• DOI: 10.1016/j.hemonc.2021.09.005
• Publication Date: 2021-10-19T16:04:17Z
• Authors: Harsha Banavasi; Seongho Kim; Samer Alkassis; Asil Daoud; Amir Laktineh; Misako Nagasaka; Ammar Sukari; Ayman O. Soubani
• Keywords: Pneumonitis

Background: Immune checkpoint inhibitors (ICIs) are the newest class of anticancer drugs. Pneumonitis is increasingly being recognized as a potential complication these agents. Methods: We conducted retrospective study patients who received ICIs at comprehensive cancer center. collected data on demographics, type malignancy, ICI agent, incidence pneumonitis up to 6 weeks after receiving clinical characteristics, and risk factors for overall survival in develop pneumonitis. Results: A total 654 during period. The most common which was given adenocarcinoma lung (29%), followed by renal cell (12%) squamous (12%). Among patients, 41% nivolumab 32% pembrolizumab. Other combination or plus chemotherapeutic were part trial involving ICI. Overall 42 (6.4%) developed within last dose treatment any agent. Of these, 81% had Grade ≥ 2 45% required hospital admission pneumonitis, with 10% them requiring intensive care unit. Overall, pembrolizumab-containing regimen, prior chemotherapy, never cancer-related surgery increased death. Conclusion: Our large shows real-life treated treatment. indicate that lower than reported previously relatively good outcomes.